A new patch-like device designed by engineers at the University of Texas at Austin boasts a number of functions, including drug delivery for patients with movement disorders such as epilepsy or Parkinson's disease.
As interest in NeuroPace's new RNS neuromodulation antiepilepsy implant ramps up, The New York Times tracked down some of the patients who use the device and have experienced major improvements in their quality of life.
California's NeuroPace gained the FDA's long-awaited signoff for its antiepilepsy neurostimulation implant, capping years of development and testing.
The FDA has approved Sunovion's Aptiom (eslicarbazepine), an add-on therapy designed to prevent epilepsy seizures. "Some patients with epilepsy do not achieve satisfactory seizure control from existing treatments," said Dr. Eric Bastings, acting director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research.
The software is the result of a three-year effort by Rhenovia and its collaborators to develop a computer model for epilepsy that is validated by laboratory experiments. Having created the software, Rhenovia is looking to market it to biopharma companies. The platform could help identify new therapeutic candidates--or reposition existing molecules--and assess their toxicology and safety profiles.
NeuroSigma will begin a Phase III pivotal trial of its Monarch system for the treatment of drug-resistant epilepsy, having received IDE approval from the FDA.
Researchers in Oregon and Boston have developed a biodegradable brain implant made of silk that is capable of delivering the compound adenosine to treat epilepsy.
Researchers looking to stem the progression of epilepsy have turned to drug-releasing brain implants made of silk, safely reducing the number of seizures by up to four times in animal trials.
California's NeuroPace raised $18 million of a sought-after $50 million in its latest funding round, cash that should help speed along the path to market for its anti-epilepsy neurostimulation device.
Acorda Therapeutics posted positive results of its first clinical feasibility study of its diazepam nasal spray to treat patients with epilepsy.